Paper Details

  1. Home
  2. Paper Details

[Favourable result for temozolomide in recurrent high-grade glioma].

Author: EntingR H, KrosJ M, Sillevis SmittP A E, TaalW, van HeuvelI, van den BentM J, van der RijtC D D

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Temozolomide was well-tolerated and effective in treating recurrent anaplastic gliomas, with a response rate of 80% for recurrent anaplastic oligodendroglioma or mixed oligo-astrocytoma. However, it had a limited role in the treatment of recurrent glioblastoma.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To describe the results of the treatment of recurrent glioma with temozolomide. DESIGN: Retrospective. METHOD: This study evaluated 77 patients with a recurrent high-grade glioma who from August 1997-December 2003 were treated with temozolomide (150-200 mg/m2/day for 5 days per 28-day c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15997692

データ提供：米国国立医学図書館（NLM）

Temozolomide: A New Hope for Recurrent Gliomas

Recurrent high-grade gliomas, a type of brain tumor, pose a significant challenge for oncologists. This research investigates the effectiveness of temozolomide, a chemotherapy drug, in treating patients with recurrent high-grade gliomas. The study retrospectively analyzed data from patients who received temozolomide after surgery and radiotherapy.

Temozolomide's Effectiveness in Treating Gliomas

The study found that temozolomide demonstrated promising results in treating recurrent anaplastic oligodendrogliomas and mixed oligo-astrocytomas. A significant proportion of patients in these groups responded to temozolomide, and a considerable number remained disease-free after 12 months of treatment. However, temozolomide had a more limited role in treating recurrent glioblastomas, with a lower response rate and shorter time to progression.

A Oasis of Hope in the Desert of Brain Tumors

This research offers a beacon of hope for patients with recurrent high-grade gliomas, particularly those with anaplastic oligodendrogliomas and mixed oligo-astrocytomas. Temozolomide, like a refreshing oasis in the desert of brain tumors, offers a potential path toward improved outcomes for these patients. However, further research is needed to understand the drug's long-term effects and to optimize treatment strategies for different types of gliomas.

Dr. Camel's Conclusion

This research provides valuable insights into the effectiveness of temozolomide in treating recurrent high-grade gliomas. While temozolomide shows promise in treating certain types of gliomas, further research is needed to optimize its use and to explore its potential in other gliomas. The journey through the desert of brain cancer research continues, seeking new and innovative treatments to improve the lives of patients facing this daunting challenge.

Date :
  1. Date Completed 2005-08-02
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

15997692

DOI: Digital Object Identifier

15997692

Related Literature

Article Analysis
・Side Effects of lomustine
SNS
PICO Info
in preparation
Languages

Dutch

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.